OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharma developing treatments for neuropathic corneal pain and inflammatory eye diseases, will present at the 33rd Annual BIO-Europe conference in Vienna, Nov. 3–5, 2025.
CEO Gary S. Jacob, Ph.D., will highlight the company’s lead candidate, urcosimod, and recent positive Phase 2 data.
The team will also hold one-on-one meetings to discuss clinical milestones and development plans.